Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Tislelizumab Administered With Alternative Dosing Schedules Plus Chemotherapy as First-line Treatment in Japanese Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

NCT07733180 is registered in ClinicalTrials.gov with BeOne Medicines as lead sponsor.

NCT NCT07733180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07733180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Tislelizumab Administered With Alternative Dosing Schedules Plus Chemotherapy as First-line Treatment in Japanese Patients With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Lead sponsor
BeOne Medicines
Phase
Phase 2
Overall status
Recruiting
Start date
September 14, 2026
Completion date
February 28, 2028
Enrollment
30 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophageal squamous cell carcinoma, metastatic esophageal squamous cell carcinoma